Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis
نویسندگان
چکیده
The efficacy and safety of aliskiren combination therapy with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in patients with hypertension and cardiovascular disease remains attractive attention. We searched the Cochrane Central Register, the Clinical Trials Registry, EMBASE, MEDLINE and PubMed for relevant literatures up to January 2017. A total of 13 randomized controlled trials (RCTs) with 12222 patients were included in this study, and the combined results indicated that aliskiren in combination therapy with ACEIs or ARBs had remarkable effects in reducing systolic blood pressure (SBP) [weighted mean differences (WMD), -4.20; 95% confidential intervals (CI) -5.44 to -2.97; I2 , 29.7%] and diastolic blood pressure (DBP: WMD, -2.09; 95% CI -2.90 to -1.27; I2 , 0%) when compared with ACEIs or ARBs monotherapy, but with significantly increased the risk of hyperkalaemia [relative risk (RR), 1.45; 95% CI 1.28 to 1.64; I2 ,10.6 %] and kidney injury ( RR, 1.92; 95% CI 1.14 to 3.21; I2 , 0%). Besides, there was no significant difference in the incidence of major cardiovascular events (RR, 0.95; 95% CI 0.89 to 1.02; I2 , 0%) between the combined therapy and ACEIs or ARBs monotherapy. In conclusion, this meta-analysis demonstrated that aliskiren in combination therapy with ACEs/ARBs could control BP effectively, but is associated with increasing risks of hyperkalaemia and kidney injury, and have no benefit in preventing of major cardiovascular events.
منابع مشابه
Correction: Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis
[This corrects the article DOI: 10.18632/oncotarget.19382.].
متن کاملPrevalence of Comorbidities in COVID-19 Patients: A Systematic Review and Meta-Analysis
Background: In this study, we aimed to assess the prevalence of comorbidities in the confirmed COVID-19 patients. Thismight help showing which comorbidity might pose the patients at risk of more severe symptoms.Methods: We searched all relevant databases on April 7th, 2020 using the keywords (“novel coronavirus” OR COVID-19OR SARS-CoV-2 OR Coronavirus) AND (comorbidities OR cl...
متن کاملEffects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients
BACKGROUND Aliskiren was shown to increase adverse events in patients with diabetes and concomitant renin-angiotensin blockade. We aim to investigate the efficacy and safety of aliskiren in patients with diabetes and increased cardiovascular risk or established cardiovascular disease. METHODS MEDLINE and Embase were searched for prospective studies comparing addition of aliskiren to standard ...
متن کاملInvestigating the prevalence rate of hypertension in Iranian men and women: A study of systematic review and meta-analysis
Introduction: Based on the serious complications which are followed, hypertension is a common and asymptomatic health problem. This study aims to present a general statistics of the rate of the prevalence of systolic and diastolic hypertension in Iranian men and women based on the age range through the systematic review and meta-analysis method. Materials and methods: In this study of system...
متن کامل